Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.05

-0.6%

Dec 9 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	1/15/2004 8:17:18 AM
From: manny t	of 52153

CRXL, Keeps making deals: Crucell Inks PER.C6 License Deal With Biogen Idec Thursday January 15, 3:03 am ET Edited Press Release AMSTERDAM -(Dow Jones)- Dutch biotechnology company Crucell N.V. said Thursday that it has signed a non-exclusive PER.C6 technology research and commercialization license agreement with Biogen Idec, Inc (NasdaqNM:BIIB - News) for the production of recombinant proteins to be used in in-house antibody discovery programs. Under the terms of the agreement, Crucell will receive upfront and annual payments, as well as royalties on net sales of products discovered using the PER.C6O technology in Biogen Idec's in-house discovery program.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next